In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Overall survival and progression-free survival outcomes appear similar for lutetium-177 and actinium-225 in select patients with mCRPC, with some differences between radioligand therapies.

Some people with advanced castrate-resistant prostate cancer now have a new option: PSMA lutetium-177, also known as lutetium Lu 177 vipivotide tetraxetan, a radiopharmaceutical ...

Modern medicine is experiencing a period of significant advancements and innovations, and at its core is radiopharmaceuticals ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen (PSMA ...

the FDA expanded the use of Pluvicto (drug name lutetium Lu 177 vipivotide tetraxetan) — for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been ...

This therapy combines a radioactive isotope such as Lutetium-177 (Lu-177) with a PSMA-targeting molecule, delivering radiation directly to prostate cancer cells while sparing healthy tissue. Patients ...

“There are many unmet needs that are discussed in this paper, including how to use PSMA PET apart from the pre-Pluvicto [lutetium-177 PSMA] setting and how to select amongst the many regimens ...